Shares of Compugen Ltd. (NASDAQ:CGEN – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the five analysts that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $8.33.
Several research firms recently weighed in on CGEN. StockNews.com began coverage on Compugen in a research report on Thursday, August 17th. They set a “hold” rating for the company. Truist Financial reaffirmed a “buy” rating and issued a $4.00 price target on shares of Compugen in a report on Wednesday, August 23rd.
Hedge Funds Weigh In On Compugen
Compugen Price Performance
Shares of NASDAQ CGEN opened at $1.14 on Friday. The stock has a market capitalization of $98.75 million, a price-to-earnings ratio of -2.85 and a beta of 2.68. The stock’s fifty day simple moving average is $1.13 and its 200 day simple moving average is $0.93. Compugen has a 52-week low of $0.51 and a 52-week high of $1.49.
Compugen (NASDAQ:CGEN – Get Free Report) last issued its earnings results on Monday, August 7th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. During the same period last year, the firm earned ($0.11) earnings per share. As a group, analysts anticipate that Compugen will post -0.34 earnings per share for the current year.
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.
- Five stocks we like better than Compugen
- How to Invest in Music Stocks
- 2 Stocks That Doubled EPS Estimates and Flashing Buy Signals
- Are Penny Stocks a Good Fit for Your Portfolio?
- Toyota vs Tesla: The Tortoise And The Hare Race Has A New Meaning
- Airline Stocks – Top Airline Stocks to Buy Now
- 5 Critical Takeaways From MongoDB’s Q2 Results for AI Investors
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.